FILTER

Refine your search with the following facets to narrow down your results.

33 Current news of PhotoCure

Phase III study results demonstrate that Hexvix cystoscopy for bladder cancer leads to significantly improved patient outcome

16-Sep-2008 - PhotoCure announced results from a phase III clinical study showing that fluorescence cystoscopy of the bladder using Hexvix (hexaminolevulinate) significantly improves the detection of non-invasive papillary bladder cancer. As a result of this improved procedure, more cancerous and precancerous ...

bladder cancer fluorescence phase III studies +1

Metvixia and Aktilite CL128 approved by FDA

30-Jun-2008 - Photocure ASA announces that Metvixia(TM) in combination with Aktilite® CL128, the LED based narrow band (630 nm) red light technology device has been approved by US Food and Drug Administration (FDA) for the treatment of actinic keratosis (AK), a pre-cancerous skin lesion. The supplement to the ...

actinic keratosis documentation food +3

Photocure receives grant of MNOK 9.1 from the Research Council of Norway

07-Apr-2008 - Photocure has been awarded NOK 9.1 million for the next three years from The Research Council of Norway (RCN) high-profile programme "User-driven Research-based Innovation" (BIA). Photocure received the grant for the project "Early detection of premalign conditions in colon when using ...

clinical trials colorectal cancer fluorescence +1

PCI Biotech strengthens the management team

06-Feb-2008 - PCI Biotech, Photocure's cancer-focused drug delivery subsidiary, strenghtens the management team and hires Per Walday as CEO. Mr Per Walday has been appointed as new CEO of PCI Biotech starting in the second quarter of 2008. Mr Anders Høgset, current CEO will take the position as Chief ...

biology drug delivery drug development +2

Photocure announces plans to de-merge PCI Biotech

19-Nov-2007 - Photocure ASA announced that its Board of Directors has decided to a plan to de-merge PCI Biotech, its cancer-focused drug delivery subsidiary. Following the completion of the de-merger process, PCI Biotech intends to seek a public listing on the Oslo Stock Exchange. PCI Biotech has developed a ...

documentation drug delivery gene therapy

New patent on Hexvix granted in US

07-Nov-2007 - Photocure has received a notification from the United States Patent and Trademark Office stating that a patent application for Hexvix in the US has been granted. The new patent is valid until 2019 and extends the current patent protection for Hexvix in the US by 3 years. President and CEO, ...

PCI Biotech file patents for combination of siRNA and the PCI technology

21-Mar-2007 - Photocure's daughter company PCI Biotech is developing a proprietary technology for site-specific drug delivery and drug enhancement called Photochemical Internalisation (PCI). PCI Biotech has, according to an agreement with Rikshospitalet-Radiumhospitalet HF, filed two patent applications ...

cancer therapy gene therapy

Photocure finalises two phase III studies on Metvix® PDT/Aktilite

19-Feb-2007 - Photocure has finalised two multicenter phase III studies comparing Metvix PDT to placebo using Photocure's light source Aktilite at leading clinical centres in the EU/US. The studies were conducted to obtain approval for Metvix in combination with Aktilite in the US (the trade name in the US is ...

actinic keratosis clinical trials Germany +2

Licensing deal between PhotoCure and GE Healthcare for bladder cancer

10-Jan-2006 - GE Healthcare and PhotoCure ASA announced a licensing agreement that grants GE Healthcare exclusive global rights outside of the US and the Nordic region to market and distribute PhotoCure's product Hexvix® (hexaminolevulinate), an optical molecular imaging agent intended for the diagnosis and ...

bladder cancer diseases food +2

PhotoCure ASA - PCI technology enhances effect of anti-cancer drug

07-Dec-2005 - PhotoCure ASA is, together with its subsidiary PCI Biotech AS, developing a proprietary technology for site-specific drug delivery called photochemical internalisation (PCI). The PCI technology uses light to activate drug delivery and can be used to enhance the effect of drugs by targeted ...

bleomycin drug delivery gene therapy